InMed Pharmaceuticals has seen a notable surge in **100% net open-market insider buying**—with zero recorded insider sales over the past year.

Key institutional 10% owners, including **ADAR1 Capital Management** and **Dr. Daniel Schneeberger**, have consistently accumulated shares, with recent filings showing multi-tranche purchases at market prices around $1.29–$1.35 per share.

Key Insider Transactions

**Heavy Accumulation by Major Holders:** Over the past year, insiders have executed over 150 open-market transactions, purchasing roughly $3.6 million worth of INM shares with zero insider selling.

**Consistent Open-Market Accumulation:** Recent SEC Form 4 filings highlight continuous buying activity by 10% owners across small-to-mid block purchases:

**ADAR1 Capital Management, LLC:** Executed multiple tranches totaling tens of thousands of shares in late September and October.

**Dr. Daniel Schneeberger:** Accumulated significant blocks (including $100K+ purchases in September).

---

What Is Driving the Buying Signal?

Insider purchases, particularly from major institutional owners on the board or holding significant stakes, typically signal strong internal confidence in a company's fundamental catalysts or underlying valuation gap.

| Catalyst / Factor | Market Context & Signal |

| --- | --- |

| Pipeline & Pipeline Synergies | Following the strategic merger with Mentari Therapeutics and ongoing clinical programs targeting Alzheimer's, ocular, and dermatological indications, major owners are positioning for key clinical milestones. |

| Valuation Disconnect | Trading near micro-cap market valuations ($7M cap) with a stock price hovering around $1.30, 10% owners are aggressively buying shares below prior multi-month highs. |

| Nasdaq Equity Compliance | InMed recently addressed Nasdaq minimum shareholders' equity notifications, a key corporate governance concern that major investors monitor closely. |

---

Investor Playbook: How to Interpret Micro-Cap Insider Signals

1. **Distinguish Between Insiders:** Purchases by 10% hedge fund owners (like ADAR1) often reflect institutional position building or capital structure support, whereas purchases directly by executive management (CEO/CFO) reflect direct operational confidence.

2. **Watch Key Technical & Regulatory Levels:** For micro-cap stocks trading under $2.00, monitor progress toward maintaining Nasdaq listing requirements alongside clinical data readouts.

3. **Assess Liquidity Risk:** Given the lower daily trading volume typical of micro-cap biotech stocks, institutional insider support provides downside stability, but high price volatility remains present.